Clinical Trials >> Pediatric Varicella Vaccine (Starting December 2024)
Pediatric Varicella Vaccine (Starting December 2024)
Varicella (i.e., chickenpox) is an acute, highly contagious infectious disease that typically affects children under 10 years of age. Effective and safe varicella vaccines have made a major global and national public health impact when used in national immunization plans in the US and many other countries worldwide.
The main purpose for the development of this varicella vaccine is to provide an additional alternative varicella vaccine as an advantage from a public health perspective to prevent varicella disease when administered as a first dose to children 12 to 15 months of age. The participant will receive the investigational varicella vaccine or the standard of care Varivax.
The study will last approximately 6 months, with 2 clinic visits and 1 phone call.
A few qualifications to participate are:
- Healthy children aged 12 to 15 months of age
- Must have received the pneumococcal immunizations
Qualified participants will:
- See a physician at no cost
- Receive the vaccine at no cost
- Receive compensation for time and travel
- web design by teaminhouse